News
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
1d
Zacks Investment Research on MSNSarepta to Report Q2 Earnings: What's in Store for the Stock?We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...
Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...
Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...
Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
11don MSN
The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...
Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping ...
Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results